Antagonizing PTGDR-1 and -2 in human lupus could be quickly accessible and safe since Laropiprant was approved by the FDA to inhibit the flushing induced by niacin to treat dyslipidemias55, and Ramatroban, a dual Thromboxane A2 receptor/PTGDR-2 antagonist can be used in allergic rhinitis56. The gene discussed is PTGDR; the disease is systemic lupus erythematosus.